15
mRNA technology involves using messenger RNA to instruct cells to produce proteins that can trigger an immune response. This technology was pivotal in developing COVID-19 vaccines, including those by Moderna and Pfizer. It allows for rapid vaccine development and adaptability, as mRNA can be engineered quickly to address emerging pathogens.
The mRNA flu vaccine works by delivering synthetic mRNA into the body, which instructs cells to create a harmless piece of the influenza virus protein. This prompts the immune system to recognize and mount a defense against the actual virus, thereby providing immunity without causing the disease.
The newly approved mRNA flu vaccine specifically targets older adults, particularly those aged 50 to 64 and individuals 65 years and older. These age groups are prioritized due to their higher risk of severe illness from influenza and related complications.
Initially, the FDA faced criticism for refusing to review Moderna's mRNA flu vaccine application. This decision drew backlash from medical professionals and scientists who advocated for the vaccine's potential benefits, leading the agency to eventually reverse its course and approve the vaccine.
mRNA vaccines offer several benefits, including rapid development and production, the ability to adapt to new variants quickly, and a strong immune response. They also do not use live virus, which eliminates the risk of causing disease in vaccinated individuals.
Traditional flu shots typically use inactivated virus or live attenuated virus to stimulate an immune response. In contrast, the mRNA flu vaccine uses genetic instructions to prompt the body to produce a viral protein, potentially leading to a more robust and targeted immune response.
The approval of the mRNA flu vaccine could significantly enhance public health by improving vaccination rates among older adults, reducing flu-related hospitalizations and deaths. It may also lead to a more effective response to seasonal flu outbreaks, ultimately lowering the burden on healthcare systems.
Moderna faced several challenges in gaining FDA approval for its mRNA flu vaccine, including initial reluctance from the FDA to review its application and public scrutiny. The company's efforts to demonstrate the vaccine's safety and efficacy were crucial in overcoming these hurdles.
This mRNA flu vaccine could change flu season outcomes by potentially offering better protection against various flu strains and reducing the severity of illness. Its innovative technology may lead to higher vaccination rates and improved public health responses during flu outbreaks.
Following FDA approval, Moderna will conduct postmarket clinical trials to confirm the vaccine's effectiveness and monitor safety in the general population. The company will also begin distribution and vaccination campaigns to ensure that older adults have access to the new vaccine.
